Explore Luminary’s pipeline
Cancer doesn’t sit still. Neither does our research.
Our product pipeline focuses on underserved cancers and autoimmune disorders. We are aggressively pursuing our BAFF CAR-T and solid tumor therapies, both utilizing Allogeneic manufacturing platforms. Here is where we stand today.
| Program | Type | Indication | Research & Preclinical Development | Phase 1&2 | Pivotal | Sponsor/Partner |
|---|---|---|---|---|---|---|
| LMY-921 | Gamma 2.0+ CAR T | B-cell Malignancies |  |
|||
| LMY-922 | Gamma 2.0+ CAR T | Autoimmune Disorders | |
|||
| LMY-232 | Gamma 2.0+ Dual Co-stim CAR T | Solid Tumors | |
|||
| LMY-920 | Autologous CAR T | Autoimmune Disorders | |
|||
| LMY-920* | Autologous CAR T | B-cell Malignancies |   |
|||
| LMY-920* | Autologous CAR T | B-cell Malignancies | |
